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Since loss of VHL is frequently detected early phase genetic event in human renal cell carcinoma, pVHL is
assumed to be indispensable for suppression of tumor initiation step. However, induction of HIF-1α, target of
pVHL E3 ligase, is more adequate to angiogenesis step after tumor mass formation. Concerning this, it has been
reported that pVHL is involved in centrosome location during metaphase and regulates ER-α signaling. Here, we
provide the evidences that pVHL-mediated ER-α suppression is critical for microtubule organizing center (MTOC)
maintaining and elevated ER-α promotes MTOC amplification through disruption of BRCA1-Rad51 interaction. In
fact, numerous MTOC in VHL- or BRCA1-deficient cells are reduced by Fulvestrant, inhibitor of ER-α expression as
well as antagonist. In addition, we reveal that activation of ER signaling can increase γ-tubulin, core factor of TuRC
and render the resistance to Taxol. Thus, Fulvestrant but not Tamoxifen, antagonist against ER-α, can restore the
Taxol sensitivity in VHL- or BRCA1-deficient cells. Our results suggest that pVHL-mediated ER-α suppression is
important for regulation of MTOC as well as drug resistance.
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The number of centrosome should be tightly regulated through entire
cell cycle for proper chromosome segregation and prevention of
aneuploidy. Thus, centrosomal amplification or mis-location have
been reported in several kinds of cancer with chromosomal instability
(CIN), which is one of strong driving force for mutation
accumulation during cancer initiation, with microsatellite instability
(MIN). For example, APC (adenomatous polypus coli) [1],
frequently mutated tumor suppressor in colon cancer, is involved in
chromosomal stability as well as β-catenin signaling [2]. BRCA1 is
also known to be involved in chromosomal stability, coupled with
DNA repair system [3,4]. However, despite importance of CIN,
regulation mechanisms in other cancers including renal cell
carcinoma (RCC) is not clearly demonstrated until now.
VHL (von Hippel-Lindau syndrome gene) is mutated over 70% of
clear cell type renal cell carcinoma from early stage [5,6], implying
that pVHL is critical for cancer initiation processes such as cell cycleregulation and maintaining of genetic materials against mutation.
However, pVHL, as the E3 ligase, promotes HIF-1α degradation,
sensing the oxygen level [7–9], suggesting that there would be
additional pVHL role in tumor initiation, because HIF-1α-mediated
angiogenesis is required at late stage. Concerning this, it has been
reported that pVHL regulates centrosome localization [10], senes-
cence [11], and ER-α signaling [12]. In addition, pVHL involves in
primary cilium maintaining, providing new insight that pVHL would
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cancer-initiation-related function of pVHL in RCC has not been
clearly demonstrated.Figure 1. VHL determines Taxol resistance. (A) VHL-positive cell lines
and VHL-negative (C2 and A498) cells were treated with Tax (3 μM) fo
Tax-induced cytotoxicity is achieved by apoptosis. Cells were treat
cytochrome C (Cyt C; green) and DAPI (blue) for cyt C release from m
cleavage-PARP was monitored. Increase of cleavage PARP in VHL-po
resistance. C2 (left panel) and C2V cells (right panel) were transf
transfection, Tax was treated for 72 hours. The cell viability was
(E) Differential expression of γ-tubulin by VHL-status. γ-tubulin was hig
comparing to VHL-positive RCC (C2V and ACHN). HCC1937 is human b
in VHL-negative cell lines. Cells were immunofluorescence (IF) staineOne of notorious feature of RCC is drug resistance, which reduces
survival of metastatic RCC below to 10% [14,15]. However, detail
molecular mechanism about the drug resistance has not beenare sensitive to Taxol (Tax) treatment. VHL-positive (ACHN and C2V)
r 72 hours. The cell viability was monitored by MTT assay. (B and C)
ed with Tax for 72 hours. After fixation, cells were stained with
itochondria to cytoplasm and nucleus (B). Under same conditions,
sitive cells (C2V and ACHN) was detected (C). (D) pVHL reduces Tax
ected with VHL expression vector or Si-VHL, respectively. After
monitored by MTT assay. EV, Empty vector; Si-Con, Si-control.
hly expressed in VHL-negative RCC cell lines (C2, A498 and A704),
reast cancer cell line. (F) γ-tubulin positive centrosome is increased
d with γ-tubulin (green) and DAPI (blue).
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ARF activity through increase of progerin [16] that would be one of
reason for drug resistance, because senescent cells are not responding
to extracellular stresses as well as apoptosis [17]. Despite this, the
resistance to Taxol, widely used microtubule de-polymerization
inhibitor for anti-cancer drug, is not explained by p14/ARF-progerin
network.
Therefore, in this study, we tried to reveal the tumor suppressive
role of pVHL in tumor initiation. In addition to cell proliferation,
elevated ER-α in VHL-deficient cells induced MTOC amplifica-
tion via disruption of BRCA1-Rad51 binding. These resultsFigure 2. VHL regulates centrosome number. (A−C) VHL down-reg
centrosome number (A), whereas VHL-transfection into C2 could red
vectors or Si-RNA for 24 hours and incubated for 72 hours. After trans
Centrosome number was counted about 50 cells (C). (D) pVHL status
24 hours. Actin was used for loading control. (E) The expression of
negative cells (C2 and A498) were transfected withWT or E3 ligase ac
(F) The effect of VHL mutants on Tax-resistance. A498 was not sen
72 hours, the transfected cell's viability was measured by MTT assay
staining, cells were fixed before stained with γ-tubulin (green) and Dindicate that proper regulation of ER-α expression by pVHL or
BRCA1 is important for MTOC regulation and prevention of
chromosomal instability.
Materials and Methods
Cell Cultures and Reagents
HEK293, MCF-7, and MDA-MB-468 (DMEM) were purchased
from ATCC (Manassas, VA). HCT116 p53−/− cell line was provided
by Dr. Vogelstein B (Johns Hopkins University). ACHN, A498,
A704 (DMEM) and HCC1937 (RPMI) cells were obtained fromulates centrosome number. Elimination of VHL in C2V increased
uce centrosome number (B). Cells were transfected with indicated
fection, cells were IF stained with γ-tubulin (green) and DAPI (blue).
determines γ-tubulin expression. Indicated vectors transfected for
γ-tubulin was regulated through E3 ligase activity of pVHL. VHL-
tivity mutated VHL (L158S, C162F and R167W) vectors for 24 hours.
sitized by mutant VHL transfection. After Tax (3 μM) treatment for
. (G) The effect of mutant VHL on centrosome amplification. For IF
API (blue).
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C2V), provided by Dr. Jung, YJ (Pusan National University). Cells
were maintained in DMEM. All kinds of cell lines were maintained in
liquid medium containing 10% FBS and 1% antibiotics at 37°C
growth chamber. General chemical inhibitors including Adriamycin
(324380) and Colcemid (234109) were purchased from Calbiochem.
B02 (SML0364), Estrogen (250155), Fulvestrant (I4409), Taxol
(T7402), Tamoxifen (T5648) and 4-OHT (H7904) were purchased
from Sigma. Antibodies against GST (sc-138), Actin (sc-1616), ER-α
(sc-8002), β-tubulin (sc-9104) and HA (sc-7392) were purchased
from Santa Cruz. Anti-γ-tubulin (T6557) and Myc (M5546) were
provided by Sigma, anti-pVHL Ab (2738) was obtained from Cell
signaling. Rad51 (05–530), BRCA1 (07–434) were purchased
from Milliopore.Vectors and Transfection
The Myc-fused BRCA1-wild type, F6 and F6 M1775R vector
were presented from Dr. Livingston, DM (Harvard Medical School).
pVHL mammalian expression vectors were obtained from Dr. Jung,
YJ (Pusan National University). The HA-tagged HIF-1α expression
vector was generously provided by Dr. Kim, YJ (Pusan National
University). The HA-fused VHL-L158S, C162F, R167W [18] and
TALEN (TAL2302, 2303, 2384, 2385) [19] vector were purchased
from Addgene. For the in vitro gene knock out, Si-RNAs against
target proteins were generated. The Si-RNA target sequences are as
follows: VHL: 5′-ACA CAG GAG CGC ATT GCA CAT-3′;
Rad51: 5′-GAG CTT GAC AAA CTA CTT-3′; HIF-1α: 5′-TAC
GTT GTG AGT GGT ATT ATT-3′; HIF-2α: 5′-CAG CAT CTT
TGA TAG CAG T-3′. For mammalian expression of these
vectors, transfection was performed using Jetpei transfection agent
(Polyplus). In brief, the vector (1.5 μg) was mixed with 1.5 μl of Jetpei
reagent in 150 nM NaCl solution. The mixture is incubated for
15 min at RT. After incubation, the mixture was added to the cell.
After 3 hours, the serum-free medium was replaced to 10% FBS
contained medium.Western Blot Analysis and Protein Interaction Studies
Proteins were extracted from cells with RIPA buffer. Samples were
applied to SDS-PAGE, and western blot analysis was performed by
means of a general protocol. Blotted membranes were incubated with
primary antibodies for 1 hour to overnight at 4°C and HRP-conjugate
species-matched secondary antibodies for 1 hour at RT. For
immunoprecipitation (IP) analysis, whole-cell lysates were incubated
first with the proper antibodies for 4 hours at 4°C and then with protein
A/G agarose beads (Invitrogen) for 2 hours at 4°C. After centrifugation
and washing with RIPA, the precipitated immunocomplexes were
subjected to SDS-PAGE and western blot analysis. To determine the
direct interaction between proteins, agarose bead-conjugated GST-γ-
tubulin (Novus) was incubated with cell lysates for 4 hours at 4°C.
Using the same procedure with IP, precipitated proteins were analyzed
by western blot analysis.Immunofluorescence Staining
Cells were seeded on a cover glass and transfected with the
indicated vectors or treated with the indicated chemicals. After fixingwith Me-OH for 30 min, the cells were incubated with blocking
buffer [PBS + anti-human-Ab (1:500)] for 1 hours. After washing
with PBS, the cells were incubated with anti-γ-tubulin or β-tubulin
antibodies in blocking buffer (1: 100 to 200) for 4 hours and
subsequently with FITC-conjugated or Rhodamine-conjugated second-
ary antibodies in blocking buffer (1: 500) for 2 hours. The nucleus
was stained by DAPI. After washing with PBS, cover glasses were
mounted with mounting solution (Vector Laboratories). The immu-
nofluorescence signal was detected through fluorescence microscopy
(Zeiss).MTT Assay
To measure the cell viability, cells were treated with the indicated
chemicals for 4 days. For the MTT assay, cells were incubated with
0.5 mg/ml of MTT solution (Calbiochem) for 4 hours at 37°C. After
removing the excess solution, the precipitated materials were
dissolved in 200 μl DMSO and quantified by measuring the
absorbance at 540 nm.Statistical Analysis
To obtain the statistical significance, we performed the Student's t test.Results
pVHL Determines Taxol Resistance
Since RCC is resistant to chemo-therapy [20], we checked the
sensitivity to Taxol in several RCC cell lines and found that VHL-
positive cell lines were sensitive to Taxol-induced cytotoxicity
(Figure 1A). Cleavage of PARP and Cytochrome C release assay
[21,22] indicated that Taxol-induced cytotoxicity in VHL-positive
cells was mediated by apoptosis (Figure 1, B and C ). To clarify the
involvement of pVHL on Taxol sensitivity, we monitored the
cytotoxicity in UMRC2 (C2) and its isogenic VHL expressed
UMRC2V (C2V), after transfection with VHL or si-VHL,
respectively, (Supplementary Figure S1A and B). Re-expression of
VHL in C2 could make be sensitized to taxol (Figure 1D), whereas
VHL knockdown provided resistance to Taxol in C2V, indicating
that pVHL was critical for determining the Taxol-sensitivity
(Figure 1D). However, loss of VHL provided only the tolerance
but not complete resistance against Taxol (Supplementary Figure
S1C), so that high concentration of Taxol could reduce cell viability
even in VHL-deficient cell. Since Taxol blocked the depolymerization
of tubulin fiber during M-phase [23], we speculated that increase of
microtubule might provide resistance to Taxol and checked the
expression of γ-tubulin in RCC cell lines. Interestingly, expression of
γ-tubulin showed the reverse-relationship with VHL except
HCC1937, human breast cancer cell line (Figure 1E ). Moreover,
γ-tubulin positive MTOCs were increased in VHL-deficient RCC
cell lines such as C2 and A498 (Figure 1F and Supplementary
Figure S1D). To know how γ-tubulin increase provide Taxol
resistance, we monitored β-tubulin in VHL-deficient A498, comparing
with VHL-intact ACHN. Taxol blocked β-tubulin fiber formation
in ACHN (Supplementary Figure S1E ). In contrast, A498 still
showed the β-tubulin fiber formation, despite Taxol-treatment
(Supplementary Figure S1E). These results suggest that increase of
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microtubule formation.pVHL Regulates MTOC Number
On the basis of MTOC amplification in VHL-deficient cells, we
measured MTOC number and observed the increase of it by si-VHL inC2V (Figure 2A and Supplementary Figure S2A) and restoration by VHL
transfection into C2 (Figure 2B, Supplementary Figure S2B, and
Figure 2C ). Consistently, γ-tubulin expression was reduced by pVHL
and increased by si-VHL (Figure 2D). Since VHL is also mutated in RCC,
we checked the effect of mutant VHL (L158S, C162F, and R167W) on
MTOC amplification and Taxol-resistance. Only WT-VHL, but not
mutated-VHL, did suppress γ-tubulin expression (Figure 2E ). Moreover,
VHL mutants did not show favorable effects on Taxol-induced cell death
Neoplasia Vol. 16, No. 12, 2014 ER-α induces MTOC amplification Jung et al. 1075and MTOC amplification in VHL-null cell lines (Figure 2, F and G and
Supplementary Figure S2C). Considering that these mutants are E3 ligase
defective form [18], E3 ligase activity is required formaintaining ofMTOC.ER-α is Responsible for MTOC Amplification
To verify the target of pVHL, responding to MTOC amplification
and Taxol-resistance, we first checked the effect of HIF-1α and HIF-
2α on Taxol-resistance. Elimination or overexpression of HIFs did
not change the sensitivity to Taxol (Figure 3A and Supplementary
Figure S3A and B). So, we focused on ER-α, which has been recently
identified as target of pVHL [13]. Si-ER-α could sensitize VHL-
deficient cell lines to Taxol and also Colcemid (Figure 3B and
Supplementary Figure S3C ), whereas ER-α overexpression rendered
the resistance to Taxol in VHL-intact ACHN (Figure 3C ). However,
pVHL and ER-α did not alter the sensitivity to Adriamycin
(Figure 3D), suggesting that pVHL-ER-α network was not linked
to general drug sensitivity, but to Taxol. To confirm the engagement
of ER-α in Taxol-resistance, we examined the Taxol-induced
cytotoxicity in C2, Caki-2 and MDA-MB-468 (ER-α negative breast
cancer cell line) and found that Fulvestrant (FST), ER-α inhibitor
and destabilizer, could sensitize these cell lines to Taxol, except
MDA-MB-468 (Supplementary Figure S3D-F). Next, we stained
MTOC using γ-tubulin in C2 cell and revealed that FST could block
the MTOC amplification (Figure 3E and Supplementary Figure
S3G). In addition, we observed the MTOC-increase by treatment of
Estrogen (Est; Figure 3F ). The inhibitory effect of FST on MTOC
amplification and γ-tubulin expression were confirmed in A498, in
which FST could reduce MTOC number (Figure 3, G–I ). However,
status of VHL, treatment of Est and FST did not alter γ-tubulin
transcripts (Supplementary Figure 3H).Estrogen Promotes MTOC Amplification
Since ER-α can induce Taxol-resistance and MTOC amplifica-
tion, we tested that Est signaling can mimic VHL-deficient condition.
To address this, we checked the MTOC number and expression of
γ-tubulin in Est-treated C2V. The treatment of Est could induceFigure 3. ER-α is responsible for centrosome amplification. (A) Tax sens
cells to Tax-induced cell death. A498 cells were transfected indicated S
was determined byMTT assay. (B) Elimination of ER-α can restore the se
Col (2 μM)-induced cell death in VHL-deficient A498 cell. A498 cells were
or Col treatment for 72 hours, the viability of transfected A498 cells w
resistance. VHL-intact ACHN cells were transfected with ER-α express
viabilitymeasurement (lower panel). (D) pVHLandER-α are involvedonly
Comparing to Tax, Adriamycin sensitivity was not affected pVHL or E
vectors. After Taxol treatment, the cell viability wasmonitored byMTT as
VHL-deficient C2 cell. C2 cells were incubatedwith FST (2 μM) or Estrog
DAPI (blue). Reduction of centrosome was detected in FST-treated cell
condition and presented as graph (F). (G and H) The effect of FST o
amplification in A498 was confirmed by IF staining with γ-tubulin Ab (
(I) Inhibitory effect of FST on γ-tubulin expression. FST reduced Est-in
expression in C2V. Treatment of Est for 72 hours could induce γ-tubulin
of γ-tubulin in C2 was not obviously detected. (K) Est promotes centros
incubatedwith Est for 72 hours and IF stainedwith γ-tubulin Ab (green) a
Tax-resistance. Tam (2 μM), FST and Tax were treated for 72 hours in VHγ-tubulin expression (Figure 3J ) and MTOC numbers (Figure 3K
and Supplementary Figure S4A and B). We could obtain the same
results from Est-treated ACHN (Supplementary Figure S4C andD). In
fact, MTOC amplification could be detected by Est-treatment in
HEK293 (Supplementary Figure S4E and F). To determine that simple
inhibition of Est-signaling is enough for restoration of MTOC and
Taxol-sensitivity, we compared the effect of Tamoxifen (Tam; Estrogen
antagonist) [24] and FST, ER-α inhibitor and destabilizer [25]. Tam
did not compensate for VHL deficiency-induced Taxol resistance
(Figure 3L), although both chemicals could block the Est-induced
proliferation (Supplementary Figure S4G ). This result indicates
that ER-α itself but not transcription activity is important for
MTOC amplification.BRCA1 is Negative Regulator on ER-α-Mediated
MTOC Amplification
To investigate how ER-α promotes MTOC amplification, we
searched the physical binding partner of ER-α, and BRCA1 was
raised as strong candidate. Indeed, BRCA1-ER-α binding has been
published [3] and we also observed the interaction of them
(Supplementary Figure S5A and B). In addition, involvement of
BRCA1 in chromosome stability regulation has been reported by
several group [4]. So, we examined the MTOC numbers in BRCA1
deficient HCC1937 [26] and found that FST could suppress
the MTOC amplification in this cell (Figure 4A and B). Indeed,
BRCA1-deficient cells showed elevated expression of γ-tubulin as
well as its mitotic binding partner Rad51 (Figure 4C ) and resistance
to Taxol, which was recovered by FST (Figure 4D and Supplementary
Figure S5C ). To confirm the role of BRCA1 inMTOC amplification,
we generated BRCA1 knock out ACHN using TALEN system.
similarly with HCC1937, BRCA1-knock out ACHN, but not in
BRCA2 knockout ACHN, showed the γ-tubulin incease and Rad51
reduction (Figure 4E ) and MTOC amplification, which diminished
by FST (Supplementary Figure S5D). To determine whether loss of
VHL could be compensated by BRCA1 or conversely, we transfected
VHL into HCC1937 or BRCA1 into A498. Interestingly, VHL
transfection into HCC1937 or BRCA1 in A498 can induce Taxol-
mediated cytotoxicity (Figure 4F and G). However, BRCA2 did notitivity is not altered by HIFs. Si-HIF-1α or HIF-2α did not sensitize A498
i-RNA for 24 hours and incubated with Tax for 72 hours. Cell viability
nsitivity to Tax and Colcemid (Colce). Si-ER-α sensitized Tax (3 μM) or
transfectedwith Si-Con (Si-control) or Si-ER-α for 24 hours. After Tax
as monitored by MTT assay. (C) ER-α overexpression induces Tax-
ion vector (upper panel) for 24 hours. MTT assay was used for cell
in Tax-sensitivity but notAdriamycin-induced cell death (Adr; 2 μg/ml).
R-α status. HCT116 p53−/− cells were transfected with indicating
say. (E and F) Fulvestrant (FST) can block centrosome amplification in
en (Est; 1 μg/ml) for 72 hours and IF stainedwith γ-tubulin (green) and
s (E). Centrosome number was counted from about 50 cells of each
n centrosome in A498. Suppression effect of FST on centrosome
G) and counting (H). Experimental condition was identical to above.
duced γ-tubulin expression in A498 cells. (J) Est induces γ-tubulin
. However, due to strong background expression, additional induction
ome amplification in VHL-intact cell lines, C2V and ACHN. Cells were
ndDAPI (blue). (L) The different effect of Tamoxifen (Tam) and FST on
L-negative A498 cells. The cell viability was estimated byMTT assay.
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indicate that VHL and BRCA1 possess replaceable and equivalent
position on ER-α regulation. In addition, activity of Mitomycin C
(MMC) was not altered by BRCA1, BRCA2 and VHL transfection in
A498 (Figure 4G), indicating that BRCA1-pVHL system is not
involved in DNA alkylation-induced cytotoxicity [27] and would be
specifically linked to mitotic cell death. In fact, BRCA1 could suppress
ER-α expression at translation level, although BRCA1 was also
reduced by ER-α (Figure 4H ).Rad51 is a Novel Binding Target of ER-α
Since BRCA1 showed equivalent role with pVHL on ER-α, our
next question is what is target of ER-α for regulating the MTOC
duplication and Taxol resistance. Since the target should be related
with MTOC regulation and BRCA1 pathway, we focused on Rad51.
It has been reported to be associated with BRCA1 in mitosis and
meiosis [28] and centrosome duplication [29]. In fact, Rad51, but not
Rad50, could sensitize Taxol-induced cell death and γ-tubulin
(Supplementary Figure S5E and F). So, we checked the effect of
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death and found that Rad51 overexpression could restore Taxol-
response, similarly with BRCA1 transfection in HCC1937 and A498
(Figure 4I and Supplementary Figure S5E). Moreover, Rad51-
induced Taxol sensitivity did not show synergic effect with FST
(Supplementary Figure S5G) or BRCA1 co-transfection (Figure 4I ),
suggesting that Rad51 overexpression is enough for abolishing the
ER-α-mediated Taxol resistance. Indeed, ER-α transfection or
elimination of VHL could suppress Rad51 expression, even in
Taxol-treated condition (Figure 4J).Activated ER-α Disrupts BRCA1-Rad51 Interaction
To confirm the effect of ER-α on Rad51, we transfected ER-α
and found that it could suppress Rad51 expression as well as induce
γ-tubulin (Figure 5A and Supplementary Figure S6A). In addition,
Rad51 could suppress γ-tubulin expression in VHL-null A498
(Supplementary Figure S6B), whereas si-Rad51 induced γ-tubulin
expression (Figure 5B) and MTOC amplification in VHL-intact
ACHN (Figure 5C and Supplementary Figure S6C ). The same
results were obtained from Rad51 inhibitor [28], B02-treated cells
(Figure 5B and D). This feature is consistent with previous literatures
that Rad51 Knock out cells show the defect in centrosome
maintaining [29]. To address the reduction of Rad51 by ER-α, we
first checked the interaction of them and found it by IP analysis
(Supplementary Figure S6D). In our previous result, we showed the
reduction of Rad51 in BRCA1-deficient condition (Figure 4C and E).
In addition, it has been revealed that BRCA1 interacts with Rad51
during mitosis and meiosis [30]. Thus, we checked the involvement
of ER-α in BRCA1-Rad51 interaction and found that Rad51 binding
region of BRCA1 was overlapped with ER-α (Supplementary Figure
S6E) and ER-α interrupted the BRCA1-Rad51 binding (Figure 5E
and F ). In addition, association of Rad51 with γ-tubulin was also
blocked by ER-α transfection (Figure 5F ). To confirm the
interaction between Rad51 and γ-tubulin, we performed the
GST-pull down assay using GST-γ-tubulin and confirmed the
interaction of them (Supplementary Figure S6F ), which wasFigure 4. BRCA1 is a negative regulator on ER-α-mediated centrosom
amplification in BRCA1-deficient HCC1937 cells. HCC1937 cells were
stained with γ-tubulin (green) and DAPI (blue) (A). The number of cent
expressionof γ-tubulin in humanbreast cancer cell lines.MDA-MB-468 (
cells were incubatedwith Est (1 μg/ml) for 72 hours. Protein expression
in HCC1937. Actin was used for loading control. (D) Sensitization of B
restored by FST-treatment (2 μM). MTT assay was used for cell viabil
BRCA1, but not BRCA1, knock out ACHN cells showed elevated γ-tubul
TALEN (TALEN2302/2303 for BRCA2 knock-out and TALEN2384/238
performed the TALEN-transfection in replica and obtained the same res
cells to Tax-induced cell death. After transfection with VHL, HCC1937 ce
throughMTT assay. (G) BRCA1 induces Tax-sensitivity in VHL-negative c
cells were transfected with indicated vectors for 24 hours and treated
suppresses ER-α expression. A498 cells were transfected with indicate
blot. (I) Rad51 sensitizes Tax-induced cell death. Overexpression of R
Rad51 did not showsynergic effectwith BRCA1.HCC1937 cells were tra
to those described above, cell viability was monitored MTT assay. (J) E
HCT116 p53−/− cells were transfected with indicated vectors or si-R
for 24 hours.weaker in VHL-null cell lysate and reduced by Est-treatment
(Supplementary Figure S6F ). These results indicated that ER-α-
mediated inhibition of BRCA1-Rad51-γ-tubulin binding was a
cause for Taxol resistance and centrosome amplification in VHL-
and BRCA1-deficient cells. To test this, we monitored the effect of
B02 on FST-induced Taxol-effect. Restoration of Taxol toxicity in
A498 was diminished by B02 (Figure 5G ). We also obtained the
similar results from C2 and C2V (Supplementary Figure S6G and
H). Next, we examined the change of interaction between BRCA1-
Rad51 in response to Est signaling and Taxol. In VHL-intact
ACHN, Taxol could induce interaction between BRCA1-Rad51
that was reduced by Estrogen treatment (Figure 5H ). In contrast,
the interaction between BRCA1-Rad51 was very weak and induced
by FST but not by Taxol in VHL-null A498 (Figure 5H ). We also
observed the increase of Rad51-γ-tubulin binding in A498 by FST
(Supplementary Figure S6I). Indeed, inhibition of ER-α using FST
could restore the interaction between BRCA1-Rad51 as well as
Rad51-γ-tubulin in response to Taxol (Figure 5I). These results
suggested that increase of BRCA1-Rad51 by Taxol might
contribute to maintaining MTOC.Increase of γ-Tubulin in VHL-Deficient Mice
To confirm the effect of VHL-ER-α signaling on MTOC
regulation and BRCA1-Rad51 system, we examined the MTOC in
VHL-deficient MEF cells, generated by Ubc-Cre-ERxpVHL flox/flox
mouse. Increase of MTOC in cre-activated condition by
treatment of 4-OHT was diminished by FST (Figure 6A and
supplementary Figure S6J ). Indeed, elimination of VHL in
MEF could induce γ-tubulin expression (Figure 6B) and showed
the resistance to Tax (Figure 6C ). We could also observe the
increase of γ-tubulin and reduction of Rad51 and BRCA1 in VHL-
deficient kidney and liver tissues (Figure 6D and restoration of them by
treatment of FST (Figure 6D). Our results are consistent with recently
published literature, in which deletion of VHL in kidney can induce
spindle mis-orientation and aneuploidy [31]. Furthermore, in this
study, we showed more detailed mechanism for dysregulation ofe amplification. (A and B) Suppressive effect of FST on centrosome
treated with FST (2 μM) for 72 hours. After treatment, cells were IF
rosome was counted about 50 cells each as conditions (B). (C) The
ER-αnegative),MCF-7 (ER-αpositive) andHCC1937 (BRCA1-deficient)
was analyzed bywestern blot. Reduction of Rad51was also detected
RCA1-deficient cells to Tax by FST. Tax-resistance of HCC1937 was
ity monitoring. (E) Deletion of BRCA1 induces γ-tubulin expression.
in expression. ACHN cells were transfected with EV (Empty vector) or
5 for BRCA1 knock-out) vectors for 5 days in selection media. We
ult from each experiment (clone #). (F) pVHL can sensitize HCC1937
lls were incubated with Tax for 72 hours andmonitored their viability
ells. Consistent with VHL, BRCA1 could reduce Tax resistance. A498
with Tax or Mitomycin C (MMC; 1.5 μM) for 72 hours. (H) BRCA1
d vectors for 24 hours. Protein expression was analyzed by western
ad51 could sensitize HCC1937 to Tax-induced cell death. However,
nsfectedwith indicated vectors for 24 hours. Under same conditions
R-α overexpression or eliminated VHL suppress Rad51 expression.
NAs for 24 hours. Adriamycin (Adr; 2 μg/ml) and Tax were treated
1078 ER-α induces MTOC amplification Jung et al. Neoplasia Vol. 16, No. 12, 2014mitotic fidelity in VHL deficient condition. During cell cycle
progression, VHL blocks ER-α-mediated cell cycle progression as
well as MTOC duplication through direct interaction (Figure 6E ).
However, in VHL-null condition, elevated ER-α blocked the
association of Rad51-BRCA1 and deregulated Rad51, which did not
block the γ-tubulin, allowed γ-tubulin-induced multi-MTOC
formation. It would be one of critical step for regulation ofchromosome segregation, chromosome instability, and cancer initiation
(Figure 6E ).
Discussion
VHL is originally identified from von Hippel Lindau syndrome and
has been revealed as tumor suppressor gene in clear cell renal
carcinoma [5,6]. Last two decades, molecular role of VHL has been
Neoplasia Vol. 16, No. 12, 2014 ER-α induces MTOC amplification Jung et al. 1079reported to be E3 ligase and inhibit HIF-1α that induces VEGF,
EPO and vascular neo-genesis related genes through its transcription
ability [32–34]. Since neo-vasculogenesis is important step for
angiogenesis in tumor progression, many researches have focused on
pVHL-HIF-1α network. However, there is raveled problemwhy VHL
should be mutated in early stage. In addition, there is no tumor
initiating mutation that promotes mutation accumulation and cell
cycle promotion in kidney cancer. Thus, we assumed that loss of
VHL would contribute to cancer initiation, independently with
HIF-1α. Concerning it, we previously showed that pVHL negatively
regulate Estrogen signaling through direct interaction and through
E3 ligase activity [13].
In this study, we showed additional role of pVHL in MTOC
regulation. Since amplification of MTOC can induce chromosomal
instability, it should be tightly regulated by tumor suppressor genes such
as APC, Bub1, and Rad family [2,35,36]. Similarly with these tumor
suppressor genes, loss of VHL can promote MTOC amplification
(Figure 1F ). In fact, while wewere preparing this paper, the role of VHL
on chromosome segregation was reported [31]. Although we and their
observations were very similar, we showed more detailed network
between VHL and ER-α-BRCA-Rad51 for MTOC duplication.
Increased ER-α byVHLdeletion blocks the BRCA1-Rad51 interaction
and induces γ-tubulin expression. In addition, loss of VHL leads to
increase ofγ-tubulin expression that is closely linked to Taxol-resistance
(Figure 1 and 2). In fact, increased γ-tubulin could generate multiple
MTOC (Figure S1E ). Thus, loss of VHL showed the resistance to
relatively high concentration of Taxol (Figure S1C). However, in this
study, we could not reveal the complete molecular mechanism about
increase of γ-tubulin/duplication of MTOC in response to Estrogen
and loss of VHL. Considering the different effect between Tamoxifen
and FST (Figure 3L) and result of our RT-PCR for γ-tubulin
(Supplementary Figure S3H), regulation of γ-tubulin would be
achieved at post-translation level. So, next, we are trying to investigate
γ-tubulin regulation and detailed molecular mechanism about
amplification of MTOC under Rad51 inactivated condition.
In particular, we are going to focusing on the role of Rad51
in inhibition of MTOC duplication and γ-tubulin increase at post-
translation level.Figure 5. Activated ER-α disrupts BRCA1-Rad51 interaction. (A) The effe
expression aswell as induced γ-tubulin. Cellswere transfectedwith EV (Em
(B) Rad51 inhibition induces γ-tubulin expression. Elimination of Rad51 or
were treated with B02 (5 μM) or transfected with Si-Rad51 for 24 hour
transfected with si-control (Si-Con) or si-Rad51 for 72 hours. cells were fix
indicates increased centrosome in si-Rd51-transfected cells. (D) Inhibition
incubatedwith B02 for 72 hours and, after fixation, IF stainedwith γ-tubulin
BRCA1. ER-α did not bind with F6 fragment of BRCA1 or M1775Rmutant
assay. Indicated vectors transfected HEK293 cell lysates were IPed by ER
Rad51 and ER-αwas increased (lane 2 and 3 in left panel). (F) ER-α disrupts
was inhibitedbyER-α. IP analysiswasused forbinding assay.EV (Emptyve
antibody. (G) B02 blocks FST-mediated Tax-sensitization. Indicated chem
measured by MTT assay. (H) Alteration of BRCA1-Rad51 binding in VH
interaction inVHLpositiveACHNcells but in VHLnegativeA498cells did no
Est (1 μg/ml) reduced interaction of between BRCA1 and Rad51 in both
indicated chemical treated A498 and ACHN. (I) FST induces the binding o
showed weak interaction of between γ-tubulin and Rad51. FST could in
indicated chemical treated A498 and ACHN.In this study, we find very interesting feature that BRCA1
deficiency-induced MTOC amplification is also compensated by
pVHL supplement or inhibition of ER-α (Figure 4). This result
indicate that BRCA1 also have similar function with pVHL on
regulation of MTOC and ER-α. However, it is not unraveled why
inherit BRCA1 mutated patients do not produce renal cell carcinoma
and rare breast cancer in VHL syndrome patients. Concerning this,
there would unrevealed tissue specific factors that would protect
MTOC amplification. Until now, we do not have any clue about this,
but it should be investigated. Our results suggest that final effector or
regulator of this pathway is Rad51 that has been revealed as essential
factor of homologous recombination and chromosome stability.
Indeed, Rad51 knock out cells produce multi-MTOC. In our system,
elevated ER-α by VHL- or BRCA1 deficiency is cause for Rad51
inactivation. ER-α can bind and block the interaction with BRCA1
(Figure 5) and suppress expression. Moreover, ER-α blocks the
interaction between Rad51 and γ-tubulin. Under normal condition,
Rad51 would bind and block the γ-tubulin induced γ-tubulin ring
complex (γ-TuRC). However, to clarify this, more intensive study
should be performed.
In summary, elevated ER-α by loss of VHL or BRCA1 binds
to Rad51 as well as BRCA1 and disrupt the BRCA1-Rad51
complex-mediated MTOC maintaining. Increased tubulin fibers
will provide the resistance to microtubule-targeted drug such as
Taxol. It would one of drug resistant mechanism in RCC as well as
BRCA1-deficient cancers. In addition, MTOC deregulation in VHL/
BRCA1 deficient cells is contributed to cancer initiation by increase of
chromosomal instability.
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of Rad51 promoted centrosome amplification. A498 and ACHN were
(green) and DAPI (blue). (E) The interaction between ER-α andwild-type
of F6 fragment. Immunoprecipitation (IP) analysis was used for binding
-α antibody. Under absence of intractable BRCA1, the binding between
the BRCA1-Rad51 binding. Interaction of between Rad51 and γ-tubulin
ctor) orER-αvectors transfectedHEK293cell lysateswere IPedbyRad51
icals were treated to A498 cells for 72 hours. The cell viability was
L status and chemical treatment. Tax (3 μM) induced BRCA1-Rad51
t. FST (2 μM) inducedBRCA1-Rad51binding inVHL-negativeA498cells.
A498 and ACHN cell. IP analysis was progressed using cell lysates of
f γ-tubulin and Rad51 in VHL-negative cell. Comparing to ACHN, A498
duce the interaction. IP analysis was progressed using cell lysates of
Figure 6. In vivo effect of VHL deficiency. (A) The centrosome number in VHL null MEF. MEF, obtained from VHLf/f xUbc-Cre-ER were
incubated with 4-OHT to eliminate VHL (for 5 days) and Est or FST for 72 hours. Cells were stained with γ-tubulin Ab (green) and DAPI for
DNA (Blue). (B) Increase of γ-tubulin by VHL elimination. Using the same samples, expression of VHL and γ-tubulin were determined by
WB analysis. Actin was used for loading control. L.E and S.E indicate long exposed and short exposed data, respectively. (C) Tax-
resistance in VHL deficient MEF. Cells were incubated with Tax for 72 hours and measured viability by MTT assay. VHL null MEF (treated
by 4-OHT) showed the resistance to Tax. (D) The effect of VHL deletion in mouse tissues. 4 week old VHLf/f xUbc-Cre-ER mice were injected
with 10 mg/kg Tam for 4 weeks and 5 mg/kg FST for 10 weeks. Cre-negative siblings (VHLf/f) were used for experimental control.
Induction of γ-tubulin and reduction of BRCA1 and Rad51 by Tam injection in VHLf/f xUbc-Cre-ER mice were restored by FST treatment.
(E) Diagram for summary. In VHL-deficient or ER-α activated condition, ER-α inhibits the association of Rad51-BRCA1 and Rad51 cannot
regulate γ-tubulin. Thus, free γ-tubulin-induced multi-centrosome formation. Moreover, amplified centrosome causes chromosome
instability and provides tumorigenic driving force.
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